Gather the evidence that actually applies
We pull the trials, identity, and literature that belong to that drug and that disease — not a generic stack of papers.
Platform
A decision,
not a dashboard.
DAO of Drugs builds TheraSignal to help biopharma teams interpret evidence and make informed therapeutic decisions. It starts with a specific drug, a specific disease, and whether that pair is worth serious attention now.
Start with your assetHow a decision is made
Check whether yesterday still holds
A past signal is not an opportunity today. We ask whether the evidence still holds as the treatment landscape, the bar to beat, and the disease definition have moved.
Name the gaps before you act
What still needs to be closed, what is already enough, and what the evidence does not yet support. Experts review and challenge the call. It is not an autonomous verdict.
What you get
Asset Scout
See where a drug has actually been studied. Nearby diseases can sit next to it on a map without being proof.
Opportunity Brief
When you already have a drug and a disease, we write what the evidence supports, what it does not, and whether it is worth attention now.
A few things we are not
This is a written call a team can review and challenge — not a chatbot, not a consulting deck, and not a CRO. Asset Scout is a landscape, not a recommendation. Nearby diseases are not opportunities until the evidence says so.